<DOC>
	<DOCNO>NCT02809118</DOCNO>
	<brief_summary>The primary objective trial confirmation efficacy AM-111 recovery severe profound idiopathic sudden sensorineural hearing loss ( ISSNHL ) .</brief_summary>
	<brief_title>Efficacy Safety AM-111 Acute Sudden Sensorineural Hearing Loss Treatment</brief_title>
	<detailed_description>This Phase III , randomize , double-blind , placebo-controlled , parallel group , multi-center , efficacy safety trial AM-111 treatment subject suffer severe profound idiopathic sudden sensorineural hearing loss . The active pharmaceutical ingredient AM-111 JNK inhibitor ( D-JNKI-1 ) , synthetic peptide consist 31 D-amino acid , act c-Jun N-terminal kinase ( JNK ) ligand . The study consist one treatment visit follow-up period day 91 . Study participant receive , topical anesthesia tympanic membrane , AM-111 0.4 mg/mL 0.8 mg/mL placebo , administer affected ear . Following administration , subject rest supine recline position 30 minute . Study participant option course oral corticosteroid .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Hearing Loss , Sensorineural</mesh_term>
	<criteria>1 . Unilateral idiopathic sudden sensorineural hearing loss ( ISSNHL ) onset within 72 hour prior study treatment ; 2 . Mean hearing threshold equal worse ( ≥ ) 60 dB average across 3 contiguous air conduction audiometric pure tone frequencies show high mean hearing loss compare unaffected contralateral ear , case history asymmetric hearing , correspond value preexist audiogram affect ear old 2 year prior ISSNHL incident ( define `` pure tone average '' , PTA ) ; 3 . Mean hearing loss equal worse ( ≥ ) 40 dB average across air conduction threshold pure tone average frequency compare unaffected contralateral ear , case history asymmetric hearing , correspond value preexist audiogram affect ear old 2 year prior ISSNHL incident ; 4 . Age ≥ 18 year day screening ; 1 . Bilateral ISSNHL ; 2 . Acute hearing loss noise trauma , barotrauma head trauma ; 3 . Airbone gap great 20 dB average 3 contiguous test frequency 4 kHz , airbone gap measurable ; 4 . History autoimmune hearing loss , radiationinduced hearing loss , endolymphatic hydrops Menière 's disease either ear ; 5 . History chronic inflammatory suppurative ear disease cholesteatoma affect ear ; 6 . Current evidence history acoustic neuroma retrocochlear damage affect ear ; 7 . History otosclerosis affect ear ; 8 . Suspected perilymph fistula membrane rupture affect ear ; 9 . Congenital hearing loss ; 10 . History ISSNHL past 2 year ; 11 . Otitis medium otitis externa ongoing end within 7 day prior study treatment ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Deafness</keyword>
	<keyword>Hearing Loss</keyword>
	<keyword>Hearing Loss , Sensorineural</keyword>
	<keyword>Ear Diseases</keyword>
	<keyword>Hearing Disorders</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neurologic Manifestations</keyword>
	<keyword>Otorhinolaryngologic Diseases</keyword>
	<keyword>Sensation Disorders</keyword>
	<keyword>Signs Symptoms</keyword>
	<keyword>Hearing Speech Impairment</keyword>
	<keyword>Hearing Loss , Unilateral</keyword>
</DOC>